Hidradenitis Suppurativa

Below is a list of our hidradenitis suppurativa studies that are currently enrolling.

A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa

Population: Patients aged eighteen to seventy-five years

Study Condition: Moderate to severe hidradenitis suppurativa (HS)
Study Design: The purpose of this study is to evaluate the efficacy of eltrekibart compared to placebo in adults with moderate to severe HS. The study duration will be up to 67 weeks. This study includes a screening period, a 16-week double-blind, placebo-controlled treatment period, a 36-week double-blind maintenance treatment period, and a 10-week follow-up period.

Compensation may be provided

Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa

Population: Subjects ≥ 16 years of age
Study Condition: Moderate to severe hidradenitis suppurativa (HS) for at least 6 months
Study Design: This is a pivotal Phase 3, global, randomized, double-blinded, placebo-controlled, multicenter study to evaluate efficacy and safety of lutikizumab in subjects 16 years of age and older with moderate to severe HS. The study comprises a 35-day Screening Period, a 16-week placebo-controlled double-blinded period (Period 1), a 36-week double-blinded extension (Period 2), and a 10-week (70 days) Follow-Up Period after last study drug dosing or an option to enter a separate long term extension study.
Compensation may be provided for participation

A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

Population: Subjects 18 years and older
Study Condition: Moderate to severe hidradenitis suppurativa (HS)
Study Design: This is a Phase 3, multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of sonelokimab in adults with moderate to severe HS. Following a Screening Period of up to 28 days, each participant will enter a Placebo-controlled Period of 16 weeks (Part A) and subsequently a Crossover/Maintenance Period of 36 weeks (Part B). In Part A subjects will be randomly assigned in a 2:1 ratio to sonelokimab 120 mg or placebo. In Part B, participants who were initially randomized to placebo will cross over to sonelokimab and will receive this treatment for the remainder of the study. An End of Treatment (EOT) Visit will be performed at Week 52. After the EOT Visit, all participants who complete Week 52 will be offered the opportunity to enter an optional long-term open label extension (OLE) study under a separate protocol. For participants who do not progress to the OLE study, a Safety Follow-up Visit will be required 8 weeks after the last dose of study treatment.
Compensation may be provided for participation

Please contact Courtney Rowley for more information regarding ongoing hidradenitis suppurativa studies.

Email: r owle@musc.edu

Phone: (843) 792-9784